AstraZeneca receives EU approval for breast cancer treatment

AstraZeneca announced on Thursday that its drug Lynparza developed jointly with the US company Merck & Co, has been approved by the European Union as an adjuvant treatment for patients with a form of genetically mutated early-stage breast cancer.

Share this post:

Share on facebook
Share on twitter
Share on pinterest
Share on whatsapp
Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner